Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials

Major Depressive Disorder in the African American Population

(2015) Rahn K. Bailey et al.   JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study

(2014) David Bakish et al.   JOURNAL OF PSYCHIATRY & NEUROSCIENCE

The Epidemiology of Depression Across Cultures

(2013) Ronald C. Kessler et al.   Annual Review of Public Health

Treatment response for acute depression is not associated with number of previous episodes: Lack of evidence for a clinical staging model for major depressive disorder

(2013) Seetal Dodd et al.   JOURNAL OF AFFECTIVE DISORDERS

Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder

(2013) Stuart A. Montgomery et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder

(2013) Gregory M. Asnis et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder

(2013) Angelo Sambunaris et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

(2013) A.L. Auclair et al.   NEUROPHARMACOLOGY

The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

(2012) Carol R. Reed et al.   CURRENT MEDICAL RESEARCH AND OPINION

Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report

(2012) S. C. Sung et al.   PSYCHOLOGICAL MEDICINE

Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression

(2011) Robert H. Howland et al.   Annals of Clinical Psychiatry

Cross-national epidemiology of DSM-IV major depressive episode

(2011) Evelyn Bromet et al.   BMC Medicine

Efficacy of Antidepressants for Late-Life Depression

(2011) Enrico Tedeschini et al.   JOURNAL OF CLINICAL PSYCHIATRY

Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report

(2011) A. J. Rush et al.   PSYCHOLOGICAL MEDICINE

Examining the role of race and ethnicity in relapse rates of major depressive disorder

(2010) Nhi-Ha T. Trinh et al.   COMPREHENSIVE PSYCHIATRY

Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder

(2010) Susan G. Kornstein et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder

(2010) Akiko Okuda et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Objective: remission of depression in primary care

(2009) Marc Ansseau et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

(2009) Stuart A. Montgomery et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Health related quality of life in recurrent depression: A comparison with a general population sample

(2009) Mascha C. ten Doesschate et al.   JOURNAL OF AFFECTIVE DISORDERS

The associations between socio-economic status and major depressive disorder among Blacks, Latinos, Asians and non-Hispanic Whites: findings from the Collaborative Psychiatric Epidemiology Studies

(2009) A. R. Gavin et al.   PSYCHOLOGICAL MEDICINE

Efficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence

(2008) J Craig Nelson et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study

(2008) Sheila M. Marcus et al.   COMPREHENSIVE PSYCHIATRY

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD

(2008) George I. Papakostas et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY